Spotlight On: Myasthenia Gravis
Myasthenia gravis issues: health disparities, quality of life, stigma, gender issues, and treatment access. (Source: WebMD Health)
Source: WebMD Health - February 24, 2023 Category: Consumer Health News Source Type: news
Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
SPRING HOUSE, PENNSYLVANIA, February 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the proof-of-concept Phase 2 open-label UNITY clinical trial for the treatment of pregnant adults at high risk for severe hemolytic disease of the fetus and newborn (HDFN). HDFN is a serious and rare condition which can cause life-threatening anemia in the fetus. It occurs when the blood types of a pregnant individual and their fetus are incompatible.1 The trial met the primary endpoint, with the majority of pregnant patients who received nipocalimab achieving a live b...
Source: Johnson and Johnson - February 8, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Balancing the Good With the Bad
Having myasthenia gravis means a lot of life adjustments. See how one person with this condition manages symptoms, practices self-care, and stays positive. (Source: WebMD Health)
Source: WebMD Health - December 15, 2022 Category: Consumer Health News Source Type: news
Managing Mental Health Challenges
A mental health professional gives tips for managing the emotional challenges of life with myasthenia gravis and saving your physical and emotional energy. (Source: WebMD Health)
Source: WebMD Health - December 15, 2022 Category: Consumer Health News Source Type: news
Facing Unpredictable Days
A person with myasthenia gravis shares how to manage the unpredictable symptoms of MG and keep a positive outlook. (Source: WebMD Health)
Source: WebMD Health - December 15, 2022 Category: Consumer Health News Source Type: news
How to Manage Your Triggers
Managing triggers is key to living well with myasthenia gravis. Learn the common triggers for MG and how to avoid or manage them. (Source: WebMD Health)
Source: WebMD Health - December 15, 2022 Category: Consumer Health News Source Type: news
What Everyday Life Is Like With MG
What’s it like to live with myasthenia gravis? A person with the condition takes you through a typical day in their life. (Source: WebMD Health)
Source: WebMD Health - December 15, 2022 Category: Consumer Health News Source Type: news
How I Handle the Fatigue
Managing fatigue is a big part of living with myasthenia gravis. See how one person deals with changes in energy levels before and during treatment. (Source: WebMD Health)
Source: WebMD Health - December 15, 2022 Category: Consumer Health News Source Type: news
Make Your Treatment Work for You
Learn tips and strategies from an expert for what to expect when you have myasthenia gravis and how to make the most of your treatment. (Source: WebMD Health)
Source: WebMD Health - December 15, 2022 Category: Consumer Health News Source Type: news
The Latest Treatments for Myasthenia Gravis
What are the new treatments for myasthenia gravis? An expert in the field gives an overview of immunotherapies and other breakthroughs. (Source: WebMD Health)
Source: WebMD Health - December 15, 2022 Category: Consumer Health News Source Type: news
Talking About Your Myasthenia Gravis
If you have myasthenia gravis, you may struggle with explaining your condition to family and friends. Here’s how to detail your condition. (Source: WebMD Health)
Source: WebMD Health - December 15, 2022 Category: Consumer Health News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer ’s disease
Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer ’sThe level of beta-amyloid removal by gantenerumab was lower than expectedTopline data will be presented at the Clinical Trials on Alzheimer ’s Disease (CTAD) ConferenceRoche is committed to the Alzheimer ’s community and will continue to develop novel diagnostics and potential treatments for Alzheimer’sBasel, 14 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) du...
Source: Roche Investor Update - November 14, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer ’s disease
Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer ’sThe level of beta-amyloid removal bygantenerumab was lower than expectedTopline data will be presented at the Clinical Trials on Alzheimer ’s Disease (CTAD) ConferenceRoche is committed to the Alzheimer ’s community and will continue to develop novel diagnostics and potential treatments for Alzheimer ’sBasel, 14 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) du...
Source: Roche Investor Update - November 14, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer ’s disease
Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer ’sThe level of beta-amyloid removal bygantenerumab was lower than expectedTopline data will be presented at the Clinical Trials on Alzheimer ’s Disease (CTAD) ConferenceRoche is committed to the Alzheimer ’s community and will continue to develop novel diagnostics and potential treatments for Alzheimer ’sBasel, 14 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) du...
Source: Roche Media News - November 14, 2022 Category: Pharmaceuticals Source Type: news
UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients
New drug application (NDA) for zilucoplan seeks approval for the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine receptor antibody positive (AChR-Ab+)
Acceptance by U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 14, 2022 Category: Drugs & Pharmacology Source Type: news
